WO2020076078A1 - 락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용 - Google Patents
락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용 Download PDFInfo
- Publication number
- WO2020076078A1 WO2020076078A1 PCT/KR2019/013260 KR2019013260W WO2020076078A1 WO 2020076078 A1 WO2020076078 A1 WO 2020076078A1 KR 2019013260 W KR2019013260 W KR 2019013260W WO 2020076078 A1 WO2020076078 A1 WO 2020076078A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- target protein
- expression vector
- microorganism
- pgsa
- Prior art date
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 106
- 244000199866 Lactobacillus casei Species 0.000 title claims abstract description 65
- 235000013958 Lactobacillus casei Nutrition 0.000 title claims abstract description 63
- 229940017800 lactobacillus casei Drugs 0.000 title claims abstract description 63
- 108091022872 aldose 1-epimerase Proteins 0.000 title claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 262
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 196
- 244000005700 microbiome Species 0.000 claims abstract description 68
- 239000013598 vector Substances 0.000 claims abstract description 59
- 101150076330 pgsA gene Proteins 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 40
- 101100059000 Bacillus subtilis (strain 168) capA gene Proteins 0.000 claims abstract description 38
- 101100083407 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) pgsA1 gene Proteins 0.000 claims abstract description 38
- 229960005486 vaccine Drugs 0.000 claims abstract description 25
- 102000003960 Ligases Human genes 0.000 claims abstract description 11
- 108090000364 Ligases Proteins 0.000 claims abstract description 11
- 235000018102 proteins Nutrition 0.000 claims description 103
- 230000014509 gene expression Effects 0.000 claims description 88
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 74
- 210000004027 cell Anatomy 0.000 claims description 71
- 241000894006 Bacteria Species 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 38
- 239000004220 glutamic acid Substances 0.000 claims description 37
- 239000004310 lactic acid Substances 0.000 claims description 37
- 235000014655 lactic acid Nutrition 0.000 claims description 37
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 31
- 235000013922 glutamic acid Nutrition 0.000 claims description 31
- 230000000813 microbial effect Effects 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 15
- 150000001413 amino acids Chemical group 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 241000192125 Firmicutes Species 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 101100059011 Bacillus subtilis (strain 168) capB gene Proteins 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 101150103033 lpxB gene Proteins 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 101100219452 Bacillus subtilis (strain 168) capC gene Proteins 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 230000009466 transformation Effects 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 101710172711 Structural protein Proteins 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 102000023732 binding proteins Human genes 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 229940019700 blood coagulation factors Drugs 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000003668 hormone analog Substances 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 230000000513 bioprotective effect Effects 0.000 claims description 2
- 230000007969 cellular immunity Effects 0.000 claims description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 2
- 230000004727 humoral immunity Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 241000233866 Fungi Species 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 description 70
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 56
- 108010052285 Membrane Proteins Proteins 0.000 description 34
- 102000018697 Membrane Proteins Human genes 0.000 description 30
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 26
- 210000004379 membrane Anatomy 0.000 description 26
- 239000012528 membrane Substances 0.000 description 26
- 108091008146 restriction endonucleases Proteins 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 102100031687 Galactose mutarotase Human genes 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 241000186660 Lactobacillus Species 0.000 description 15
- 229940039696 lactobacillus Drugs 0.000 description 15
- 230000028327 secretion Effects 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 10
- 244000063299 Bacillus subtilis Species 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 8
- 102000004895 Lipoproteins Human genes 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 6
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000004020 intracellular membrane Anatomy 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- HJCUTNIGJHJGCF-UHFFFAOYSA-N 9,10-dihydroacridine Chemical compound C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 4
- 241000186012 Bifidobacterium breve Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 108700005078 Synthetic Genes Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 108010083364 chungkookjang Proteins 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 101710116435 Outer membrane protein Proteins 0.000 description 3
- 108020005091 Replication Origin Proteins 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003495 flagella Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 101150096615 pgsA1 gene Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- QWYXSNDFUIZFDB-UHFFFAOYSA-N (2,3,6-trifluorophenyl) 10-methyl-9h-acridine-9-carboxylate Chemical compound C12=CC=CC=C2N(C)C2=CC=CC=C2C1C(=O)OC1=C(F)C=CC(F)=C1F QWYXSNDFUIZFDB-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010000916 Fimbriae Proteins Proteins 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940028617 conventional vaccine Drugs 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960003983 diphtheria toxoid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 108010063679 ice nucleation protein Proteins 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241001213452 Bifidobacterium longum NCC2705 Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 241000304138 Enterococcus faecalis V583 Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
- 108090000828 Insulysin Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010036940 Levansucrase Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001219481 Spongospora subterranea Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191982 Staphylococcus hyicus Species 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- BWKOZPVPARTQIV-UHFFFAOYSA-N azanium;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [NH4+].OC(=O)CC(O)(C(O)=O)CC([O-])=O BWKOZPVPARTQIV-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 108010085318 carboxymethylcellulase Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010072250 fimbrillin Proteins 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- -1 fter Species 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y501/00—Racemaces and epimerases (5.1)
- C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
- C12Y501/03003—Aldose 1-epimerase (5.1.3.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a promoter of a galactose mutarotase gene derived from Lactobacillus casei , and more specifically, Lactobacillus casei represented by the nucleotide sequence of SEQ ID NO: 1. It relates to a promoter of the derived galactose mutarotase gene, an expression vector containing the promoter, and a microorganism transformed with the expression vector.
- the present invention relates to a new vector that effectively expresses a foreign protein on the surface of a microorganism using an extracellular membrane protein (pgsA) involved in the synthesis of polygamma glutamic acid derived from a strain of the genus Bacillus, and furthermore, the present invention is a strain of the genus Bacillus It relates to a method for producing a protein that expresses a foreign protein on the surface of a microorganism using an extracellular membrane protein involved in the synthesis of the derived polygamma glutamic acid.
- pgsA extracellular membrane protein
- Lactic acid bacteria the most important microbial group among food microorganisms, are microorganisms that have been used in various foods and have been proven to be safe (GRAS: generally recognized as safe), and have plasmids, bacteriophage, and transposons to introduce themselves. It is possible to develop a vector, and it is easy to transform by a method commonly used in the art, and it can be said to be the most suitable strain for use as an edible product, since the edible selection marker genes are also secured.
- lactic acid bacteria have effects such as intestinal harmful bacterium suppression and intestinal action, blood cholesterol reduction function, nutritional value enhancement, pathogen infection suppression action, liver cirrhosis improvement action, anti-cancer action, anti-aging action, and immune-enhancing action through macrophage activation. Have.
- lactic acid bacteria are vaccines because it is known that a large amount of components contained in lactic acid bacteria, such as unmethylated CpG DNA, lipidochoic acid, and peptidoglycan, act as adjuvants. Its usefulness as a vehicle is highly regarded.
- lactic acid bacteria have a number of advantages in that they can induce intestinal mucosal immunity because they are resistant to bile acids and gastric acids and can transmit antigens to the intestine (Jos FMK Seegers, Trends Biotechnol., Vol. 20, pp 508- 515, 2002).
- lactobacillus is suitable as a carrier of beccin, such as confirming the efficacy of treating diseases using secretion-expressing strains (Lothar Steidler et al., Nat. Biotechnol. Vol. 21, pp 785-789, 2003). .
- cell surface expression refers to a technology that fuses a protein or peptide with an appropriate surface expression motif to express on the surface of Gram-negative, positive bacteria, fungi, yeast, and animal cells (Lee SY, et al., Trends) Biotechnol., 21: 4552, 2003).
- the first cell surface expression technology was expressed by fusion of a peptide or small protein with pIII of a filamentous phage using a relatively simple phage, which is called a surface-expression system. .
- Cell surface expression using phage was used for screening of antibodies or screening of epitope, high-affinity ligand, etc., however, the size of proteins that could be expressed on the surface of phage was relatively limited, revealing limitations. Therefore, as an alternative, cell surface expression using bacteria has been developed. It is a field that stably expresses foreign proteins on the surface of microorganisms by using surface proteins of microorganisms such as bacteria and yeast as a surface anchoring motif.
- the appropriate surface protein and the foreign protein are linked to each other at the gene level so that the fusion protein is biosynthesized, and they stably pass through the inner membrane and adhere to the cell surface.
- a protein having the following properties as a matrix for surface expression First, it has a secretion signal that can pass through the intracellular membrane at the N-terminus, and second, it is used on the cell outer membrane surface. It must have a targeting signal that can be stably attached. Third, it can be expressed in a large amount on the cell surface within a range that does not adversely affect cell growth, and finally, protein activity can be high.
- a secretion signal through which the biosynthesized protein in the cell can pass through the cell membrane must be on the primary sequence of the protein.
- it in the case of Gram-negative bacteria, it must be seated so that it passes through the intracellular membrane and the cell membrane space and is attached to the extracellular membrane and protrudes out of the membrane.
- proteins having such secretion signals and targeting signals that settle on the cell surface include, for example, surface proteins, special enzymes, and toxin proteins. In fact, if the secretion signals and target signals of these proteins are used together with an appropriate promoter, the proteins can be successfully expressed on the surface of bacteria.
- the surface proteins of bacteria used for the surface expression of foreign proteins can be largely divided into four types: extracellular membrane proteins, lipoproteins, secreted proteins, and cell surface organ proteins.
- extracellular membrane proteins lipoproteins
- secreted proteins cell surface organ proteins.
- cell surface organ proteins cell surface organ proteins.
- surface proteins mainly present in Gram-negative bacteria such as LamB, PhoE, and OmpA.
- LamB LamB
- PhoE PhoE
- OmpA the size of the protein that can be structurally inserted is limited because the foreign protein is inserted into a loop protruding from the cell surface.
- the C-terminus and the N-terminus of the foreign protein to be inserted must be positioned three-dimensionally close, there is a problem in that the distance between the two ends with a connecting peptide should be close when the distance is long.
- Lipid proteins are also used as surface proteins for surface expression.
- the lipoprotein of E. coli has a secretion signal at its N-terminus and can pass through the intracellular membrane, and the terminal cysteine (L-cysteine) is covalently attached to the extracellular membrane lipid or the intracellular membrane lipid directly.
- the main lipoprotein, Lpp is bound to the N-terminus by the extracellular membrane and the C-terminus by the cell wall (peptidoglycan, PG) .When connected to the extracellular membrane protein OmpA fragment, it can stably secrete foreign proteins to the extracellular membrane to express the surface. [Francisco et al., Proc. Natl. Acad. Sci.
- Another lipoprotein, TraT was used to surface-express peptides such as the C3 epitope of poliovirus using these properties of lipoproteins [Felici et al., J. Mol. Biol., 222: 301-310 (1991)].
- cell wall-attached lipoprotein (PAL) whose exact function is not yet known, was also used for surface expression of recombinant antibodies [Fuchs et al., Bio / Technology, 9: 1369-1372 (1991)]. In this case, the C-terminus of the PAL was connected to the cell wall, and the N-terminus was connected to the recombinant antibody to express the fusion protein.
- the secreted protein passing through the extracellular membrane can also be used as a surface protein, but in the case of Gram-negative bacteria, the secreted protein is not developed, and only a few secreted proteins have proteins involved in the specific secretion mechanism, so that the extracellular membrane passes Is helping.
- pullulanase of the genus Klebsiella is a lipoprotein whose N-terminus is replaced with fat, attached to the extracellular membrane, and then completely secreted into cell culture. Konacker et al.
- the IgA protease from the pathogenic microorganism Neisseria which has a unique secretion system, has a signal that allows the protease present at the N-terminus to settle on the extracellular membrane in a fragment present at the C-terminus. Once reaching the extracellular membrane, the protease that protrudes on the cell surface is secreted into the cell culture medium by its hydrolysis ability. Klauser et al. Used this IgA protease-fragment to stably express a cholera toxin B subunit of about 12 kDa on the cell surface [Klauser et al., EMBO J., 9: 1991-1999 (1990)]. However, secretion of the fusion protein was suppressed by protein folding in the cell membrane space during the secretion process.
- cell organelles that are present on the cell surface and can be applied to the surface expression include flagella, pili, and fimbriae.
- flagella protein Flagellin
- flagella protein a constituent subunit of flagella, peptides derived from cholera toxin B subunit and hepatitis B virus were stably expressed, and they reacted strongly with antibodies against them [Newton et al., Science, 244: 70-72 (1989)].
- a lipase derived from Staphylococcus hyicus is used as a secretion signal
- protein A derived from Staphylococcus aureus is used as a membrane-attaching matrix, resulting in an 80 amino acid malaria antigen (malaria) Blood stage antigen) and streptococcus protein G-derived albumin-attached proteins have been effectively expressed on the surface of Gram-positive bacteria.
- the appropriate extracellular membrane protein and the foreign protein are linked to each other at the gene level to induce fusion proteins to be biosynthesized, and they stably pass through the intracellular membrane. It should be kept attached to the extracellular membrane.
- the surface-expressing matrix that satisfies all the above conditions has not been developed yet, and so far is a level that compensates for the disadvantages of the above-described cases.
- the present inventors utilize the synthetic complex gene (pgsBCA) of polygamma glutamic acid derived from a strain of the genus Bacillus subtilis var. Chungkookjang as a new surface expression matrix, and a new vector for effectively expressing foreign proteins on the surface of microorganisms and A method of expressing a target protein on the surface of a microorganism transformed with a vector has been developed (Korean Patent Registration No. 0469800).
- pgsBCA synthetic complex gene of polygamma glutamic acid derived from a strain of the genus Bacillus subtilis var. Chungkookjang
- the present inventors have developed a vector capable of stably high-expressing an antigen or an antigenic determinant in the lactobacillus using the surface-expressing matrix described in the patent, and thus the human body is friendly to the immune response efficiently and efficiently because the antigen is exposed on the surface of the lactobacillus.
- the promoter of the galactose mutarotase gene is compared to the previously used promoter.
- the main object of the present invention is to provide a promoter derived from Lactobacillus casei ( Lactobacillus casei ) that induces an increase in expression of a target gene.
- Another object of the present invention is to provide an expression vector characterized in that the gene encoding the promoter and the target protein is linked.
- Another object of the present invention is to provide a method for producing a target protein using the microorganism transformed with the expression vector and the transformed microorganism.
- Another object of the present invention is to provide a method for producing a microbial vaccine using the transformed microorganism.
- Another object of the present invention is to select an extracellular membrane protein involved in the synthesis of polygamma glutamic acid derived from a strain of the genus Bacillus as a surface expression parent capable of expressing a large amount of foreign protein on the surface of a microorganism, and using it as a foreign expression protein or It is intended to provide a method for preparing a surface expression vector of a target protein capable of expressing a peptide on a microbial surface, and efficiently expressing a foreign protein on the surface of a transformant in various transformants transformed with the target protein.
- the present invention provides a promoter of galactose mutarotase gene derived from Lactobacillus casei .
- the promoter may be characterized in that represented by SEQ ID NO: 1.
- the present invention also provides an expression vector and a microorganism transformed with the expression vector, wherein the target gene is linked to the end of the promoter.
- the present invention also provides a microbial surface expression vector and a microorganism transformed with the surface expression vector to which the promoter, the polygamma glutamic acid synthetase complex gene and the gene encoding the target protein are linked.
- the target protein may be characterized as an antigen.
- the target protein is a hormone, a hormone analog, an enzyme, an enzyme inhibitor, a signal transduction protein or a portion thereof, an antibody or a portion thereof, a short chain antibody, a binding protein, a binding domain, a peptide, an antigen, an adhesion protein, a structural protein, a regulatory protein, a toxin It may be characterized in that it is any one selected from the group consisting of proteins, cytokines, transcriptional regulatory factors, blood coagulation factors and plant bioprotective proteins.
- the poly-gamma-glutamic acid synthase complex gene may be characterized by at least one of pgsA, pgsB and pgsC.
- the present invention also provides a method for expressing a target protein on the surface of a microorganism, characterized by culturing the transformed microorganism.
- the present invention further comprises: (a) culturing the microorganism transformed with the microorganism surface expression vector to surface express the antigen on the microorganism surface; And (b) recovering the microorganism on which the antigen is surface-expressed.
- the present invention provides a surface expression vector of a target protein comprising a gene encoding a polygamma glutamic acid synthetase complex pgsA and a target protein.
- the gene pgsA may be characterized as derived from a strain of the genus Bacillus that produces polygamma glutamic acid.
- the gene pgsA encoding the polygammaglutamic acid synthetase complex may be characterized by having any one of nucleotide sequences of SEQ ID NOs: 18 to 22 and 29 to 31.
- the gene pgsA encoding the polygammaglutamic acid synthetase complex may be characterized by having any one of nucleotide sequences of SEQ ID NOs: 18 to 21 and 29 to 31.
- a linker is inserted into the terminal portion of the gene pgsA, and a gene encoding a target protein is inserted into the inserted linker.
- the target protein may be characterized in that a portion of the amino acid sequence of the target protein is removed or position-specific mutated to favor surface expression.
- the present invention also provides a microorganism transformed with the surface expression vector.
- the microorganism used for transformation may be characterized in that it is modified so as not to produce intracellular or extracellular proteolytic enzymes involved in decomposing the expressed target protein so as to favor the cell surface expression of the target protein. .
- the microorganism may be characterized in that the lactic acid bacteria.
- the lactic acid bacteria may include the genus Lactobacillus, Streptococcus genus and Bifidobacterium genus.
- the genus Lactobacillus is Lactobacillus acidophilus , L. casei , Lactobacillus plantarum , L. ferementum , Lactobacillus L. delbrueckii , L. johnsonii LJI , L. reuteri and L. bulgaricus ;
- the genus Streptococcus is S. thermophilus ;
- the genus Bifidobacterium is B. infantis, B.
- B. longum B. psuedolongum
- Bifidobacterium breve B. breve
- Bifidobacterium lactis Bb-12 B. lactis Bb-12
- Bifidobacterium adolescentis can be used as hosts. And more preferably the genus Lactobacillus.
- the present invention also provides a method for expressing a cell surface of a target protein comprising culturing the transformed microorganism to express the target protein on the cell surface and recovering the cell expressing the target protein on the surface.
- the target protein is a hormone, a hormone analog, an enzyme, an enzyme inhibitor, a signal transduction protein or a portion thereof, an antibody or a portion thereof, a single chain antibody, a binding protein, a binding domain, a peptide, an antigen, an adhesion protein, a structural protein, and regulation It may be characterized in that it is any one selected from the group consisting of proteins, toxin proteins, cytokines, transcription regulatory factors, blood coagulation factors and plant biodefense-inducing proteins.
- the present invention also provides a method characterized by inducing humoral immunity or cellular immunity by administering cells expressing the antigen on the surface to a vertebrate other than humans by the above method.
- the present invention is also produced by the above method, characterized in that by administering cells expressing the antigen on the surface to vertebrates other than humans to induce an immune response, and recovering antibodies generated by the immune response. Methods for making antibodies in animals are provided.
- the present invention also provides a surface expression vector of a target protein, characterized in that the vector is applied to Gram-negative bacteria or Gram-positive bacteria.
- the present invention also, (a) preparing a recombinant vector by inserting a gene encoding a target protein into a vector for microbial surface expression; (b) transforming Gram-negative or Gram-positive host cells with the recombinant vector; And (c) culturing the transformed host cell to express the target protein on the surface of the host cell, thereby providing a method for expressing the target protein on the surface of the gram-negative or gram-positive host cell.
- the present invention has an effect of providing a galactose mutarotase promoter derived from Lactobacillus casei capable of highly expressing a target protein in lactic acid bacteria and a vector for expression using the promoter. Since the vector contains a gene for surface-expressing the target protein, in the transformant using the vector, the target protein can be effectively expressed on the surface of the cell, and lactic acid bacteria can be utilized as a vaccine carrier.
- the surface expression vector of the target protein can stably express the target protein, and the surface expression vector according to the present invention constantly expresses the target protein while simultaneously expressing the target protein. It can be useful for the production of antigens for vaccine production.
- Figure 1 shows the method of obtaining the galactose mutarotase (galactose mutarotase) promoter of the present invention.
- Figure 2 shows the genetic map of the vector for surface expression constructed using the galactose mutarotase (galactose mutarotase) promoter of the present invention.
- Figure 3 Compared with the lactic acid bacteria transformed with the expression vector of the present invention, the degree of expression of the target protein between each promoter is shown through Western blotting.
- Figure 5 shows the genetic map of the surface expression vector, pKV-Pald-PgsA-EGFP, using Lactobacillus casei as a host according to the present invention.
- Figure 6 shows the genetic map of the surface expression vector (pKV-Pald-pgsA1), PgsA motif 1-60 a.a -EGFP as a host of Lactobacillus casei according to the present invention.
- Figure 7 shows the genetic map of the surface expression vector (pKV-Pald-pgsA2), PgsA motif 1-70 a.a -EGFP, which is a host of Lactobacillus casei according to the present invention.
- Figure 8 shows the genetic map of the surface expression vector (pKV-Pald-pgsA3), PgsA motif 1-80 a.a -EGFP as a host of Lactobacillus casei according to the present invention.
- FIG. 9 Surface expression vector (pKV-Pald-pgsA5), host of Lactobacillus casei according to the present invention, shows a genetic map of PgsA motif 1-100 a.a -EGFP.
- Fig. 10 shows the genetic map of the surface expression vector (pKV-Pald-pgsA5), pKV-PgsA 1-188 a.a-EGFP, which hosts Lactobacillus casei according to the present invention as a host.
- Fig. 11 shows the genetic map of the surface expression vector (pKV-Pald-pgsA6), PgsA motif 25-60 a.a -EGFP, which hosts Lactobacillus casei according to the present invention as a host.
- Fig. 12 shows the genetic map of the surface expression vector (pKV-Pald-pgsA7), PgsA motif 25-70 a.a -EGFP, which is a host of Lactobacillus casei according to the present invention.
- Figure 13 shows the genetic map of the surface expression vector (pKV-Pald-pgsA8), PgsA motif 25-100 a.a -EGFP as a host of Lactobacillus casei according to the present invention.
- Figure 14 shows a Western blotting photograph showing the surface expression of EGFP protein in Lactobacillus casei transformed with the surface expression vectors pKV-Pald-pgsA1 to pKV-Pald-pgsA8 of the present invention.
- Example 2 Construction of EGFP protein surface expression vector (pKV-Pgm-pgsA-EGFP) using a galactose mutarotase promoter
- an expression vector of the EGFP protein that is expressed by the galactose mutarotase promoter a vector having RepE capable of replicating in E. coli and Lactobacillus casei as a replication origin, a galactose mutaro derived from Lactobacillus casei After inserting the Tase promoter, pgsA, a surface expression parent derived from Bacillus subtilis var.
- Chungkookjang is introduced downstream of the promoter, and restriction of BamHI and XbaI capable of inserting a target gene into the carboxy terminus of pgsA
- the enzyme site was added to prepare a pKV-Pgm-pgsA vector containing the galactose mutarotase promoter.
- the pgsA gene was used as disclosed in Korean Patent Registration No. 0469800.
- the EGFP gene was obtained after PCR using the synthetic EGFP gene fragment as a template and using SEQ ID NO: 4 and SEQ ID NO: 5 as primers.
- the present invention in one aspect, relates to a promoter of a galactose mutarotase gene derived from Lactobacillus casei .
- the galactose mutarotase promoter of the present invention is a promoter that induces the expression of the galactose mutarotase gene present in Lactobacillus casei.
- the promoter includes a portion in which RNA polymerase binds to induce transcription initiation, and since the degree of RNA synthesis is determined according to the base sequence of the promoter, the expression intensity of the gene may be different depending on the promoter.
- the EGFP gene is inserted into an expression vector containing the promoter and an existing aldolase promoter, respectively, and lactose is prepared using the prepared vectors.
- Bacillus casei was transformed, the expression level of EGFP induced by each promoter was compared through Western blotting. As a result, it was confirmed that the expression level of EGFP was effectively increased in the transformant of the vector containing the galactose mutarotase promoter, and the expression induction intensity of the promoter of the present invention was also stronger than the existing aldolase promoter.
- the expression level of EGFP was effectively increased in the transformant of the vector containing the galactose mutarotase promoter, and the expression induction intensity of the promoter of the present invention was also stronger than the existing aldolase promoter.
- the present invention relates to an expression vector containing a gene encoding the galactose mutarotase promoter and a target protein and a microorganism transformed with the expression vector.
- the expression vector usually requires at least a promoter that enables transcription, a gene that expresses the target protein downstream of the promoter, a gene that can self-replicate and amplify in the microorganism, and a selectable marker gene to select the desired vector.
- the genes, excluding the target gene may vary depending on the backbone of the vector and the selected host.
- the minimally necessary genes in vector construction are well known to those skilled in the art, and can be easily selected according to gene expression conditions and purposes.
- the backbone of the vector can be used, such as those having a replication origin of pWV01, pAM ⁇ 1, but is not limited thereto.
- Various methods and means can be used to insert a vector or DNA sequence that is intended for gene expression, including a target gene as well as an additional regulatory site, into a suitable host cell.
- biochemical methods such as transformation, transfection, conjugation, protoplast fusion, and calcium phosphate precipitation, or diethylminoehtyl (DEAE) dextran, or electroporation Physical methods such as can be used.
- DEAE diethylminoehtyl
- a target gene After inserting the expression vector into an appropriate host cell, a target gene can be expressed using a selection medium suitable for growth of a host containing an antibiotic capable of selecting only transformants using conventional techniques known in the art. Transformants containing the present vector can be selected.
- the present invention provides a microorganism surface expression vector and a microorganism transformed with the surface expression vector to which the galactose mutarotase promoter, a polygamma glutamate synthetase complex gene and a gene encoding a target protein are linked. It is about.
- Downstream of the promoter contains the gene of the polygammaglutamic acid synthetase complex, which is a surface expression parent, which is located between the promoter and the target gene on the DNA sequence of the vector. Since the gene of the surface-expressing mother is encoded with an amino acid, it is linked to the first half of the target protein and functions to induce the expressed protein to bind with the lipid of the cell membrane, so it plays a decisive role in surface expression of the target protein.
- the method of linking the gene of the surface-expressing parent with the promoter and the target gene can be easily carried out by those skilled in the art such as PCR (polymerase chain reaction), restriction enzyme digestion and ligation. Technology can be used.
- 'host', or 'microorganism' refers to lactic acid bacteria, which are gram-positive bacteria of probiotic, and the general probiotic microorganism selection criteria include (i) human-derived microorganisms; (ii) stable to bile, acid, enzymes and oxygen; (iii) have the ability to adhere to the intestinal mucosa; (iv) have the ability to form colonies in the digestive tract; (v) be able to produce antibacterial substances; And (vi) efficacy or stability can be demonstrated.
- lactic acid bacteria are friendly and harmless bacteria that grow in the human body.
- the strain when a transformant using lactic acid bacteria as a host is applied to the human body and used for the purpose of gene transfer or protein transfer for the prevention or treatment of disease, unlike the conventional vaccine manufacturing method using the strain, the strain is not toxicized Or no step of detoxification is required.
- the microorganism may include the genus Lactobacillus, Streptococcus genus, and Bifidobacterium genus.
- the genus Lactobacillus is Lactobacillus acidophilus , L. casei , Lactobacillus plantarum , L. ferementum , Lactobacillus L. delbrueckii , L. johnsonii LJI, L. reuteri and L. bulgaricus ;
- the genus Streptococcus is S. thermophilus ;
- Bifidobacterium Bifidobacterium bonus B. bifidum
- Bifidobacterium rongeom B. longum
- Bifidobacterium pseudo rongeom B. psuedolongum
- Bifidobacterium breve B. breve
- Bifidobacterium lactis Bb-12 B. lactis Bb-12
- Bifidobacterium adolescentis can be used as hosts. And more preferably the genus Lactobacillus.
- an expression vector (pKV-Pgm-pgsA-EGFP) capable of expressing the EGFP gene as a target gene was prepared by including the base sequence linked to the promoter and the surface expression parent pgsA, and the expression vector was lactobacillus.
- a transformant expressing EGFP was prepared by inserting it into Kasay.
- the target protein expressed by the promoter having the improved gene expression ability of the present invention is expressed on the surface of the cell, so the transformed microorganism of the present invention can be used as a vaccine.
- the present invention relates to a method for producing a microbial vaccine, characterized by using lactic acid bacteria transformed with the surface expression vector.
- Vaccines are drugs that are used to stimulate the immune system by using living organisms for the purpose of preventing disease.
- Immune activation refers to a process for efficiently removing an antigen by stimulating antibody production, stimulation of T-lymphocytes, or other immune cells (eg, macrophages) in an organism.
- the target of administration of the transformed microbial vaccine expressing a target protein as an antigen may be a mammal, more preferably a human.
- the preparation of the vaccine composition can be carried out using standard techniques, and the dosage suitable for the operator varies depending on the antigenicity of the gene product and may be an amount sufficient to induce the typical immune response of the existing vaccine, and through routine experimental procedures. Needs can be easily determined.
- a typical initial vaccine dose is 0.001 to 1 mg antigen per kg body weight, increasing the amount or using multiple doses as needed to provide the desired level of protection.
- the amount can be determined by a person skilled in the art and depends on factors such as formulation method, mode of administration, age, body weight, sex, morbidity, food, time of administration, route of administration, rate of excretion, and response sensitivity. It can also be prescribed in various ways.
- the antigenic material In order for the vaccine to be effective in producing antibodies, the antigenic material must be introduced into the body so that the antibody-producing mechanism of the vaccinated subject can be realized. Therefore, for the immune response, the microorganism carrier of the gene product must first be introduced into the body.
- administration methods such as intravenous injection, intramuscular injection, and subcutaneous injection are possible. It is preferred to administer.
- the vaccine composition for oral administration of the vaccine composition to the administerer, it is useful to be provided in a lyophilic form, for example in capsule form.
- the capsule is provided as an enteric coating comprising Eudragate S, Eudragate L, cellulose acetate, cellulose phthalate or hydroxy propylmethyl cellulose.
- the capsules may be used by themselves or recomposed of a lyophilic material such as a suspension before administration. It is effective to reconstitute in a buffer of pH suitable for the survival of the transformed microorganism. It may be useful to administer the sodium bicarbonate preparation prior to each vaccine administration to protect the transformed microorganisms and vaccines from gastric acid.
- the vaccine can be prepared for parenteral administration, intranasal administration, or intramammary administration.
- the transformed lactic acid bacteria containing the promoter of the present invention and containing a gene expressing a target protein capable of acting as an antigen forms colonies on the mucous membranes of the digestive system so that the desired efficacy can be obtained. It maintains the desired transgenic properties, and can simultaneously administer selected antibiotics in the vector for smooth colony formation.
- undesired lactic acid bacteria that do not have a vector that can be derived in the process of dividing the transformant The occurrence can be controlled.
- the above screening method can be easily carried out by conventional techniques in the art, and the selective antibiotics that can be used in the above process may vary depending on the antibiotic gene included in the expression vector.
- a surface expression vector (pKV-Pald-PgsA-EGFP) ) was obtained by performing PCR using the primers of SEQ ID NOs: 8 to 17 as a template.
- each PgsA1 to A5 motif fragment has a nucleotide sequence of SEQ ID NOs: 18 to 22.
- the surface expression vector (pKV-Pald-PgsA-EGFP) of SEQ ID NOs: 23 to 28 PCR was performed using primers to obtain.
- each PgsA motif fragment has a nucleotide sequence of SEQ ID NOs: 29 to 31.
- the present invention selects an extracellular membrane protein involved in the synthesis of polygamma glutamic acid derived from a strain of the genus Bacillus as a new surface expression parent capable of expressing a large amount of foreign protein on the surface of a microorganism, and uses it to microbial foreign protein or peptide It is an object of the present invention to provide a surface expression vector capable of expressing on a surface, and to provide a method for efficiently expressing a foreign protein on the surface of a transformant in various transformants transformed therewith.
- the present invention provides a microbial surface expression vector comprising the gene pgsA constituting the polygamma glutamic acid synthetase complex and a strain transformed by the vector.
- the present invention also provides a method of expressing a foreign protein on the surface of a transformed strain using the microbial surface expression vector to achieve the above object.
- the protein encoded by the gene pgsA is an extracellular membrane protein present in Bacillus, Bacillus subtilis IFO3336; Nattobacteria; Biochem. Biophy. Research Comm., 263, 6-12, 1999), Bacillus licheniformis (Bacillus) licheniformis ATCC9945; Biotech. Bioeng. 57 (4), 430-437, 1998), edible, water-soluble, anionic, produced from Bacillus anthracis (J. Bacteriology, 171, 722-730, 1989), etc. It is a protein involved in the synthesis of poly-gamma-glutamic acid, a biodegradable polymer.
- the extracellular membrane protein isolated from bacteria consists of a total of 922 amino acids, consisting of pgsB, pgsC and pgsA, pgsB is 393 amino acids, pgsC is 149 amino acids and pgsA is 380 It is composed of amino acids.
- Ashiuchi et al. Have observed the synthesis of polygamma glutamic acid from Bacillus natto bacteria, cloned and transformed into E. coli to observe the synthesis of polygamma glutamic acid in E. coli [Ashiuchi et al., Biochem. Biophy. Res. Communications, 263: 6-12 (1999)].
- pgsB is a amide ligase of the complex-constituent protein, and the N-terminal specific amino acid of pgsB interacts with the cell membrane or cell wall, and in the case of pgsA, it has a hydrophilic specific amino acid sequence at the N-terminal and C-terminal.
- these amino acid sequences have secretion signals and target and adhesion signals that can pass through the intracellular membrane.
- the extracellular membrane protein involved in the synthesis of polygammaglutamic acid has many advantages as a surface-expressing parent that expresses foreign proteins on the cell surface due to its amino acid primary sequence structure and properties:
- polygamma glutamic acid The extracellular membrane protein involved in the synthesis of polygamma glutamic acid can be expressed in large quantities on the cell surface for the synthesis and secretion of the extracellular
- the extracellular membrane protein involved in the synthesis of the expressed polygamma glutamic acid is a cell cycle resting period In the case of pgsA, structurally, it protrudes on the cell surface.
- the extracellular membrane protein involved in the synthesis of polygamma glutamic acid is a surface of Gram-positive bacteria. But it can be stably expressed on the surface of Gram-negative bacteria. There are advantages such.
- An object of the present invention is to provide a useful vector capable of expressing a foreign protein on the surface of a bacterium by using the properties of an extracellular membrane protein involved in the synthesis of polygamma glutamic acid.
- the surface expression vector of the target protein of the present invention includes a secretory signal and a target signal possessed on the primary sequence of the extracellular membrane protein involved in the synthesis of polygamma glutamic acid.
- the present invention has an object to provide a method for expressing a foreign protein on the surface of a microorganism using a surface expression vector using the characteristics of an extracellular membrane protein involved in the synthesis of polygamma glutamic acid.
- the present invention expresses a foreign protein on the surface of a microorganism by using an extracellular membrane protein involved in the synthesis of polygamma glutamic acid, so that the foreign protein can be efficiently used without going through a cell crushing or protein separation and purification process. It provides a method of manufacturing.
- the "target protein” or “foreign protein” means a protein that cannot normally exist in a transformed host cell expressing the protein.
- the protein is referred to as a foreign protein or a target protein.
- the target protein preferably includes an infectious microorganism, an antigen derived from an immune disease or an antigen derived from a tumor, for example, a fungal pathogen, bacteria, parasites, intestinal parasites, helminths, viruses or allergens, etc. It may, but is not limited to this.
- the antigen is tetanus toxoid (tetanus toxoid), influenza virus hemagglutinin (hemagglutinin) or nucleoprotein, diphtheria toxoid (diphtheria toxoid), gp120 or fragment of HIV, gag protein of HIV, IgA pro Protease, insulin peptide B, spongospora subterranea antigen, Vibriose antigen, Salmonella antigen, Pneumococcus, Respiratory syncytial virus (RSV) antigen , Hemophilus influenza outer membrane protein, Streptococcus pneumoniae antigen, Helicobacter pylori urease, Neisseria meningitidis pilin , Pilin of Neseria gonorrhoeae, melanoma-associated protein (TRP2, MAGE-1, MAGE-3, gp100, tyrosine) Human papillomavirus (te
- the foreign protein produced by the surface expression method of the present invention can be provided for various uses.
- This use includes effective production of antibodies and enzymes, as well as production of peptide libraries to screen for antigens, attached or adsorbed proteins, and new bioactive substances.
- the surface expression vector using the synthetic gene of polygamma glutamic acid of the present invention can be applied to all strains to express foreign proteins on the surface of microorganisms, preferably Gram-negative bacteria, more preferably E. coli, Salmonella typhi , Salmonella typhimurium, Vibrimo cholera, Mycobacterium bovis, Shigella, and Gram-positive bacteria, preferably Bacillus, Lactobacillus, Lactococcus, Staphylococcus, Listeria monocytogenes, Strapococcus strain, etc. Can be applied. All foreign protein production methods using the above strains are included in the scope of the present invention.
- various recognition sites of all or some restriction enzymes can be inserted into the N-terminus or C-terminus of the synthetic gene of polygamma glutamic acid, and the surface expression vectors into which these restriction enzyme sites are inserted are all within the scope of the present invention. Is included.
- the present invention includes pgsA, a polygamma-glutamic acid synthetic gene derived from a strain of the genus Bacillus, and inserts a restriction enzyme recognition site at the C-terminus of pgsA, thereby making it possible to clone various foreign protein genes easily, surface expression vector pKV- Pald-pgsA1 to pKV-Pald-pgsA8 are provided.
- the present invention is composed of pgsA, which is a complex of the extracellular membrane protein among the complexes of the extracellular membrane proteins involved in the synthesis of polygamma glutamic acid, and connects the N-terminus of the EGFP protein to the C-terminus of pgsA to convert the EGFP protein into a fusion protein form.
- Surface expression vectors pKV-Pald-pgsA1 to pKV-Pald-pgsA8 that can be expressed on the surface of Gram-positive bacteria are provided.
- the gene pgsA of the extracellular membrane protein involved in the synthesis of polygamma glutamic acid was obtained from Bacillus subtilis var. Chungkookjang (KCTC 0697BP), but the gene is all Bacillus producing polygamma glutamic acid. It is also included in the scope of the present invention to obtain a pgsA from the genus strain to prepare a vector or surface express a foreign protein. For example, using the pgsA gene derived from another strain having 80% or more homology to the base sequence of the pgsA gene present in Bacillus subtilis cheonggukjang, vector production or surface expression of foreign proteins will also be included in the scope of the present invention. .
- enhanced green fluorescent protein was selected and confirmed as a model protein.
- EGFP enhanced green fluorescent protein
- "EGFP (enhanced green fluorescent protein) gene” is a gene that makes it easy to observe cells expressing the protein by emitting green light in vivo, and has an advantage that can be observed with a fluorescent microscope.
- GFP is a green fluorescent protein originating from jellyfish (Aequorea Victoria) and has been used as an important marker of gene expression in various research fields.
- EGFP is a mutant of GFP, replacing the original GFP's 64th phenylalanine amino acid sequence with Leucine, and the 65th located Serine amino acid sequence with Threonine, which is more than the original GFP. It has the advantage of emitting a strong fluorescent signal.
- the present inventors prepared the surface expression vector by inserting the EGFP gene into the pKV-Pald-pgsA1 to pKV-Pald-pgsA8 recombinant vectors prepared above, transformed Lactobacillus casei, and cultured to induce expression by inducing the expression. Then, a certain amount of the culture solution was collected to obtain a protein. The obtained protein was analyzed by SDS-PAGE, and Western blotting was performed using an anti-EGFP antibody. As a result, the protein EGFP was added to the pKV-Pald-pgsA1 to pKV-Pald-pgsA8 recombinant vectors prepared above. Was successfully inserted and confirmed to be expressed on the cell surface.
- EGFP protein was used as a foreign protein, but any other protein such as other enzymes, antigens, antibodies, adhesion proteins, or adsorption proteins may be foreign proteins.
- the pgsA gene was used as a motif for producing a surface expression vector, but it was found that similar results can be obtained even when pgsB, pgsC or a combination thereof is used (WO2003 / 014360) It will be apparent to those skilled in the art as identified in.
- Example 1 Securing a galactose mutarotase promoter derived from Lactobacillus casei
- Lactobacillus casei is a basic medium, MRS medium (1% casein hydrolysate, 1.5% yeast extract, 2% dextrose, 0.2% ammonium citric acid, 0.5% sodium acetate, 0.01% magnesium sulfate, 0.05% manganese sulfate and Cultured in 0.2% dipotassium phosphate, Acumedia Manufacturers, Inc.), and the solution obtained by crushing the cultured Lactobacillus 1x10 9 cells was used as a PCR template.
- MRS medium 1% casein hydrolysate, 1.5% yeast extract, 2% dextrose, 0.2% ammonium citric acid, 0.5% sodium acetate, 0.01% magnesium sulfate, 0.05% manganese sulfate and Cultured in 0.2% dipotassium phosphate, Acumedia Manufacturers, Inc.
- Example 2 Construction of EGFP protein surface expression vector (pKV-Pgm-pgsA-EGFP) using a galactose mutarotase promoter
- a vector having RepE capable of replicating in E. coli and Lactobacillus casei as a replication origin is a galactose mutaro derived from Lactobacillus casei
- pgsA a surface expression parent derived from Bacillus subtilis var.
- Chungkookjang is introduced downstream of the promoter, and restriction of BamHI and XbaI capable of inserting a target gene into the carboxy terminus of pgsA
- the enzyme site was added to prepare a pKV-Pgm-pgsA vector containing the galactose mutarotase promoter.
- the pgsA gene was used as disclosed in Korean Patent Registration No. 0469800.
- the EGFP gene was obtained after PCR using the synthetic EGFP gene fragment as a template and using SEQ ID NO: 4 and SEQ ID NO: 5 as primers.
- Example 3 Confirmation of expression and induction intensity of target protein through Western blotting
- the pKV-Pgm-pgsA-EGFP expression vector prepared in Example 2 was transformed with Lactobacillus casei, and the transformed recombinant Lactobacillus casei was cultured to confirm expression of the EGFP protein.
- an EGFP gene as a reporter gene is linked to each promoter to construct an expression vector, and Lactobacillus casei Each was transformed. And the amount of EGFP expression was compared by Western blotting.
- the recombinant Lactobacillus casei transformed with the surface expression vector of the present invention was incubated at 30 ° C in MRS medium (Lactobacillus MRS, Becton Dickinson and Company Sparks, USA) to induce surface expression of EGFP protein.
- MRS medium Libacillus MRS, Becton Dickinson and Company Sparks, USA
- the whole cells of the cultured Lactobacillus casei were subjected to SDS-polyacrylamide gel electrophoresis and Western blotting using specific antibodies against EGFP to confirm the expression of the fusion protein.
- a sample was prepared by denaturing the transformed recombinant Lactobacillus casei cells in which expression was induced with a protein obtained at the same cell concentration, and analyzing this by SDS-polyacrylamide gel electrophoresis, followed by fractionation. Proteins were transferred to PVDF (polyvinylidene-difluoride membranes, Bio-Rad) membranes. The PVDF membrane transferred with the proteins was blocked in a blocking buffer solution (50 mM Tris-HCl, 5% skim milk, pH 8.0) for 1 hour, and then the polyclonal primary antibody derived from each rabbit against EGFP was blocked. Diluted 1000 times in a buffer solution and reacted for 1 hour.
- a blocking buffer solution 50 mM Tris-HCl, 5% skim milk, pH 8.0
- the membrane was washed with a buffer solution, and the secondary antibody against the HRP (Horseradish Peroxidase) -conjugated rabbit-derived antibody was diluted 10000 times in a blocking buffer solution and reacted for 1 hour.
- HRP Haseradish Peroxidase
- the membrane is washed with a buffer solution, and a substrate (Lumigen PS-3 acridan, H 2 0 2 ) is added to the washed membrane for about 2 minutes to develop color. The binding was confirmed.
- Figure 3 shows the results of performing Western blotting to confirm the expression level of the EGFP protein in the recombinant Lactobacillus casei cells transformed with the cell surface expression vector of the present invention.
- Lane SM is Protein size marker
- Lane 1 is Lactobacillus casei (empty vector)
- Lane 2 and 3 are Lactobacillus casei (pKV-Pgm-pgsA-EGFP)
- Lane 4 is Lactobacillus casei (pKV-Pald-pgsA-EGFP), respectively. Expression.
- the expression of the target protein was confirmed in the expression vector of pKV-Pgm-pgsA-EGFP (Lane 2 and 3) of the present invention as well as the expression amount. It was confirmed that it was more excellent.
- the galactose mutarotase promoter of the present invention stably expresses a target protein in an expression vector and can express it more strongly compared to the Aldoalse promoter (FIG. 3).
- Example 4 Confirmation of microbial surface expression of two target proteins using a confocal fluorescence microscope
- the fluorescence image was observed through a confocal microscope (Confocal microscopy, Carl Zeiss LSM800).
- Recombinant Lactobacillus casei transformed with the surface expression vector (pKV-Pgm-pgsA-EGFP) of the present invention is cultured on MRS medium (Lactobacillus MRS, Becton Dickinson and Company Sparks, USA), and subjected to static incubation at 30 ° C. Expression was induced. Then, after binding with a specific antibody of EGFP, immunostaining with Alexa488 (green) confirmed cell surface expression of EGFP under a confocal microscope.
- the expression vector of the present invention can be utilized in the production of a microbial vaccine because transformation of lactic acid bacteria does not require a step of detoxification or non-toxication of the strain, unlike the conventional vaccine production method, and expresses the target protein more strongly. It is expected to be.
- EGFP expression vector a gene encoding EGFP protein was inserted into the C-terminal of PgsA using a surface expression vector prepared in pKV-Pald-PgsA-E7 (refer to Korean Patent No. 10-1471043).
- a vector pKV-Pald-PgsA-EGFP capable of surface expression in lactic acid bacteria was obtained.
- the HPV16 E7 gene fused with pgsA was removed from the pKV-Pald-PgsA-E7 vector and a gene encoding EGFP was inserted. It was obtained by performing PCR using the synthetic EGFP gene fragment as a template using SEQ ID NO: 6 and SEQ ID NO: 7 as primers.
- a segment of 755 bp containing the EGFP gene was obtained, the 5 'end of the segment contained a BamHI restriction enzyme site, and the 3' end of the segment contained an XbaI restriction enzyme site.
- the obtained DNA fragment was digested with BamHI and XbaI restriction enzymes to obtain a 741 bp fragment.
- pKV-Pald-PgsA-E7 was cut with BamHI and XbaI to remove the HPV16 E7 gene portion and secure the vector portion.
- the pKV-Pald-PgsA-EGFP was completed by linking the DNA fragment containing the E7 gene digested with BamHI and XbaI with the vector digested with the same restriction enzyme (FIG. 5).
- the surface expression vector prepared in Example 5 (pKV-Pald-PgsA-EGFP) was used to improve the PgsA gene as a fragment so that it can more stably exhibit high expression rates in lactic acid bacteria hosts.
- a surface expression vector (pKV-Pald-PgsA-EGFP) ) was obtained by performing PCR using the following primer as a template.
- PgsA motif 1-80 a.a
- each PgsA1 to A5 motif fragment has the following nucleotide sequence.
- PgsA 1-60 a a fragment sequence (PgsA1)
- PgsA 1-70 a fragment sequence (PgsA2)
- PgsA 1-80 a fragment sequence (PgsA3)
- PgsA 1-100 a.a fragment sequence (PgsA4)
- PgsA 1-188 a a fragment sequence (PgsA5)
- the pKV-Pald-PgsA-EGFP was cleaved with SphI and BamHI to obtain a vector portion from which the aldolase promoter and the PgsA gene portion were removed.
- the improved vector was completed by linking the DNA fragment containing each PgsA motif fragment gene with a vector digested with the same restriction enzyme (Figs. 6 to 10).
- a surface expression vector (pKV-Pald-PgsA-EGFP) was used as a template using the following primers. PCR was performed to obtain.
- each PgsA motif fragment has the following nucleotide sequence.
- PgsA 25-60 a a fragment sequence (PgsA6)
- the pKV-Pald-PgsA-EGFP was cut with EcoRV and BamHI to obtain a vector portion from which the PgsA gene portion was removed.
- Lactobacillus casei was transformed with the PgsA motif improved surface expression vector prepared in Example 5, and the transformed recombinant Lactobacillus casei was cultured to confirm expression of EGFP protein.
- the expression of the EGFP protein fused with any of the fragments pgsA1 to A8 improved in the transformed recombinant Lactobacillus casei was examined.
- Recombinant Lactobacillus casei transformed with the PgsA motif fragment surface expression vector is statically cultured at 30 ° C at MRS medium (Lactobacillus MRS, Becton Dickinson and Company Sparks, USA), and any of the gene fragments pgsA1 to A8 synthesizing polygamma glutamic acid at 30 ° C. Surface expression of EGFP protein fused with one C-terminus was induced.
- the whole cells of the cultured Lactobacillus casei were subjected to Western blotting using SDS-polyacrylamide gel electrophoresis and specific antibodies against EGFP to confirm expression of the fusion protein.
- a sample was prepared by denaturing the transformed recombinant Lactobacillus casei cells in which expression was induced with a protein obtained at the same cell concentration, and analyzing this by SDS-polyacrylamide gel electrophoresis, followed by fractionation. Proteins were transferred to PVDF (polyvinylidene-difluoride membranes, Bio-Rad) membranes. The PVDF membrane on which the proteins have been transferred is blocked by shaking in a blocking buffer solution (50 mM Tris hydrochloric acid, 5% skim milk, pH 8.0) for 1 hour, followed by blocking buffer of a polyclonal primary antibody derived from rabbit against EGFP The solution was diluted 1000-fold and reacted for 1 hour.
- a blocking buffer solution 50 mM Tris hydrochloric acid, 5% skim milk, pH 8.0
- the membrane was washed with a buffer solution, and the secondary antibody against HRP-conjugated rabbit was diluted 10000 times in a blocking buffer solution and reacted for 1 hour.
- the membrane is washed with a buffer solution, and a substrate (lumigen PS-3 acridan, H202) is added to the washed membrane for about 2 minutes to develop color.
- a substrate lumigen PS-3 acridan, H202
- FIG. 14 shows the expression pattern (lane 6 and 11) in the Lactobacillus casei according to the pKV-Pald-pgsA recombinant expression vector into which the unmodified pgsA set as a control was compared with the present invention (lane 6 and 11) and the improved pgsA1 according to the present invention
- the expression patterns (lanes 1 to 5 and lanes 7 to 10) in Lactobacillus casei according to the pKV-Pald-pgsA1 to A8 recombinant expression vector into which A8 is inserted are shown.
- lane 1 in FIG. 14 is a transformed recombinant Lactobacillus casei expressing EGFP on PgsA motif 1-60 aa
- lane 2 is PgsA motif 1-70 aa
- lane 3 is PgsA motif 1-80 aa
- Lane 4 is the expression of recombinant Lactobacillus casei transformed with EGFP on PgsA motif 1-100 aa
- Lane 5 shows protein expression of recombinant Lactobacillus casei transformed with EGFP on PgsA motif 1-188 a.a.
- Lane 6 shows protein expression of recombinant Lactobacillus casei transformed with pKV-Pald-PgsA-EGFP.
- lane 7 in FIG. 14 is a transformed recombinant Lactobacillus casei expressing EGFP on PgsA motif 25-60 aa
- lane 8 is PgsA motif 25-70 aa
- lane 9 is EGFP on PgsA motif 25-100 aa Is the expression of the transformed recombinant Lactobacillus casei.
- Lane 10 shows protein expression of recombinant Lactobacillus casei transformed with EGFP on PgsA motif 1-188 a.a.
- Lane 11 shows protein expression of recombinant Lactobacillus casei transformed with pKV-Pald-PgsA-EGFP.
- the present invention uses a Lactobacillus casei derived galactose mutarotase (galactose mutarotase) promoter and an extracellular membrane protein (pgsA) involved in the synthesis of polygamma glutamic acid derived from a strain of the genus Bacillus (pgsA)
- the vector contains a gene that surface-expresses the target protein, so in the transformant using the vector, the target protein can be effectively expressed on the surface of the cell, thereby vaccinating lactic acid bacteria
- It can be used as a carrier, and the surface expression vector of the target protein can stably express the target protein, and the surface expression vector according to the present invention constantly expresses the target protein while simultaneously expressing the target protein in need Antigen production for vaccine production
- the industrial applicability in that it can exist useful.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (25)
- 락토바실러스 카제이(Lactobacillus casei) 유래 갈락토오스 뮤타로테이즈(galactose mutarotase) 유전자의 프로모터.
- 제1항에 있어서, 서열번호 1의 염기서열을 가지는 것을 특징으로 하는 프로모터.
- 제1항의 프로모터 및 목적단백질을 코딩하는 유전자를 포함하는 발현벡터.
- 제3항의 발현벡터로 형질전환된 미생물.
- 제1항의 프로모터, 폴리감마글루탐산 합성효소 복합체 유전자 및 목적단백질을 코딩하는 유전자가 연결되어 있는 것을 특징으로 하는 미생물 표면 발현벡터.
- 제5항에 있어서, 목적단백질은 항원인 것을 특징으로 하는 미생물 표면 발현벡터.
- 제5항에 있어서, 폴리감마글루탐산 합성효소 복합체 유전자는 pgsA, pgsB 및 pgsC 중 어느 하나 이상인 것을 특징으로 하는 미생물 표면 발현벡터.
- 제5항 내지 제7항 중 어느 한 항의 미생물 표면 발현벡터로 형질전환된 미생물.
- 제8항에 있어서, 미생물은 유산균인 것을 특징으로 하는 미생물.
- 제5항에 있어서, 상기 폴리감마글루탐산 합성효소 복합체를 코드하는 유전자는 pgsA이고, 서열번호 18 내지 21 및 29 내지 31 중 어느 하나의 염기서열을 가지는 것을 특징으로 하는 목적단백질의 표면발현벡터.
- 제10항에 있어서, 상기 유전자 pgsA는 폴리감마글루탐산을 생산하는 바실러스 속 균주에서 유래한 것을 특징으로 하는 목적단백질의 표면발현벡터.
- 제10항에 있어서, 상기 폴리감마글루탐산 합성효소 복합체를 코드하는 유전자 pgsA는 서열번호 22의 염기서열을 가지는 것을 특징으로 하는 목적단백질의 표면발현벡터.
- 제10항에 있어서, 상기 유전자 pgsA의 말단부위에 링커가 삽입되어 있고, 상기 삽입된 링커에 목적단백질을 코딩하는 유전자가 삽입되어 있는 것을 특징으로 하는 목적단백질의 표면발현벡터.
- 제10항에 있어서, 상기 목적단백질은 표면발현에 유리하도록 목적단백질의 아미노산 서열 중 일부분이 제거되거나 위치 특이적으로 돌연변이된 것임을 특징으로 하는 목적단백질의 표면발현벡터.
- 제10항 내지 제14항 중 어느 한 항에 있어서, 상기 벡터는 그람음성균 또는 그람양성균에 적용되는 것을 특징으로 하는 목적단백질의 표면발현벡터.
- 제10항 내지 제14항 중 어느 한 항의 표면발현벡터로 형질전환된 미생물.
- 제16항에 있어서, 형질전환에 사용된 미생물은 목적단백질의 세포 표면발현에 유리하도록, 발현된 목적단백질을 분해하는데 관련된 세포 내 또는 세포 외의 단백질 분해효소를 생산하지 못하도록 변형된 것임을 특징으로 하는 형질전환된 미생물.
- 제16항에 있어서, 미생물은 유산균인 것을 특징으로 하는 형질전환된 미생물.
- 제8항의 형질전환된 미생물을 배양하는 것을 특징으로 하는 목적단백질을 미생물 표면에 발현시키는 방법.
- 다음 단계를 포함하는 미생물 백신의 제조방법:(a) 제6항의 미생물 표면 발현벡터로 형질전환된 미생물을 배양하여 미생물 표면에 항원을 표면발현하는 단계;및(b) 상기 항원이 표면발현된 미생물을 회수하는 단계.
- 제20항에 있어서, 미생물은 유산균인 것을 특징으로 하는 방법.
- 제16항의 형질전환된 미생물을 배양하여 목적단백질을 세포표면에 발현하는 단계 및 목적단백질이 표면에 발현된 세포를 회수하는 단계를 포함하는 목적단백질의 세포표면 발현방법.
- 제22항에 있어서, 목적단백질은 호르몬, 호르몬 유사체, 효소, 효소저해제, 신호전달 단백질 혹은 그 일부분, 항체 혹은 그 일부분, 단쇄항체, 결합단백질, 결합도메인, 펩타이드, 항원, 부착단백질, 구조단백질, 조절단백질, 독소단백질, 사이토카인, 전사조절 인자, 혈액응고 인자 및 식물 생체방어 유도 단백질로 구성된 그룹으로부터 선택되는 어느 하나인 것을 특징으로 하는 방법.
- 제23항의 방법에 의해 제조되고, 항원이 표면에 발현된 세포를 인간을 제외한 척추동물에 투여하여 체액성 면역 또는 세포성 면역을 유도하는 것을 특징으로 하는 방법.
- 하기의 단계를 포함하는 것을 특징으로 하는 그람음성 또는 그람양성 숙주세포의 표면에 목적단백질을 발현시키는 방법 :(a) 제24항의 목적단백질의 표면발현벡터에 목적단백질을 코드하는 유전자를 삽입하여 재조합 벡터를 제조하는 단계;(b) 상기 재조합 벡터로 그람음성 또는 그람양성 숙주세포를 형질전환하는 단계; 및(c) 상기 형질전환된 숙주세포를 배양하여 목적단백질을 숙주세포 표면에 발현하는 단계.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/281,743 US20220033812A1 (en) | 2018-10-10 | 2019-10-10 | Surface expression vector for constitutive high-expression using promoter of galactose mutarotase gene derived from lactobacillus casei, and use thereof |
JP2021518738A JP7147060B2 (ja) | 2018-10-10 | 2019-10-10 | ラクトバチルス・カゼイ由来ガラクトース・ムタロターゼ遺伝子のプロモーターを用いた常時的高発現表面発現ベクターおよびその利用 |
EP19871372.9A EP3865578A4 (en) | 2018-10-10 | 2019-10-10 | SURFACE EXPRESSION VECTOR FOR CONSTITUTIVE HIGH EXPRESSION USING A GALACTOSE MUTAROTASE GENE PROMOTER DERIVED FROM LACTOBACILLUS CASEI, AND USE THEREOF |
CN201980075582.0A CN113330119A (zh) | 2018-10-10 | 2019-10-10 | 使用源自干酪乳杆菌的半乳糖变旋酶基因启动子用于组成型高表达的表面表达载体及其用途 |
KR1020217010523A KR102594583B1 (ko) | 2018-10-10 | 2019-10-10 | 락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0120546 | 2018-10-10 | ||
KR20180120546 | 2018-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020076078A1 true WO2020076078A1 (ko) | 2020-04-16 |
Family
ID=70164212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/013260 WO2020076078A1 (ko) | 2018-10-10 | 2019-10-10 | 락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220033812A1 (ko) |
EP (1) | EP3865578A4 (ko) |
JP (1) | JP7147060B2 (ko) |
KR (1) | KR102594583B1 (ko) |
CN (1) | CN113330119A (ko) |
WO (1) | WO2020076078A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7170129B2 (ja) * | 2018-10-10 | 2022-11-11 | バイオリーダース コーポレイション | ラクトバチルス・カゼイ由来の二種類のプロモーターを用いた二種の目的タンパク質の同時表面発現ベクター、およびこれを用いたタンパク質の微生物表面発現方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010214A1 (en) | 1991-11-15 | 1993-05-27 | George Georgiou | Expression of proteins on bacterial surface |
WO1993024636A1 (en) | 1992-05-29 | 1993-12-09 | The University Of British Columbia | Use of protein oprf for bacterial cell surface expression of oligopeptides |
WO1994010330A1 (en) | 1992-11-03 | 1994-05-11 | Rea, Teresa, Stanek | Fibronectin binding protein as well as its preparation |
EP0603672A2 (de) | 1992-12-23 | 1994-06-29 | BEHRINGWERKE Aktiengesellschaft | Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung |
US5356797A (en) | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
WO1995004069A1 (en) | 1993-07-30 | 1995-02-09 | Affymax Technologies N.V. | Biotinylation of proteins |
WO2003014360A1 (en) | 2001-08-10 | 2003-02-20 | Bioleaders Corporation | SURFACE EXPRESSION VECTORS HAVING pgsBCA, THE GENE CODING POLY-GAMMA-GLUTAMATE SYNTHETASE, AND A METHOD FOR EXPRESSION OF TARGET PROTEIN AT THE SURFACE OF MICROORGANISM USING THE VECTOR |
KR20080086161A (ko) * | 2007-03-22 | 2008-09-25 | 주식회사 바이오리더스 | 신규 항시적 고발현 프로모터 및 그 용도 |
WO2010001363A1 (en) * | 2008-07-04 | 2010-01-07 | Terranol A/S | Microorganism expressing aldose-1-epimerase |
KR101471043B1 (ko) | 2009-01-08 | 2014-12-09 | 주식회사 바이오리더스 | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 |
KR20150092921A (ko) * | 2014-02-06 | 2015-08-17 | 단국대학교 천안캠퍼스 산학협력단 | 담즙산에 의해 발현이 유도되는 프로모터를 포함하는 셔틀벡터 및 이를 포함하는 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7255855B2 (en) * | 2004-02-27 | 2007-08-14 | Bioleaders Corporation | Surface expression method of peptides P5 and Anal3 using the gene encoding poly-gamma-glutamate synthetase |
KR100784261B1 (ko) * | 2006-01-02 | 2007-12-11 | 한국과학기술원 | 탄저균의 포자외막 단백질을 이용한 목적단백질의 미생물표면발현방법 |
US20140045235A1 (en) * | 2012-08-12 | 2014-02-13 | Wisconsin Alumi Research Foundation | Construction of a lactobacillus casei ethanologen |
JP6553963B2 (ja) | 2014-09-05 | 2019-07-31 | 花王株式会社 | 改変スターメレラ属微生物 |
KR20200000972A (ko) * | 2018-06-26 | 2020-01-06 | 주식회사 바이오리더스 | 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를 이용한 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 |
JP7170129B2 (ja) * | 2018-10-10 | 2022-11-11 | バイオリーダース コーポレイション | ラクトバチルス・カゼイ由来の二種類のプロモーターを用いた二種の目的タンパク質の同時表面発現ベクター、およびこれを用いたタンパク質の微生物表面発現方法 |
CN114702559A (zh) * | 2022-04-02 | 2022-07-05 | 江西师范大学 | 枯草芽孢杆菌蛋白PgsA及其在表面展示系统中的应用 |
-
2019
- 2019-10-10 US US17/281,743 patent/US20220033812A1/en active Pending
- 2019-10-10 WO PCT/KR2019/013260 patent/WO2020076078A1/ko unknown
- 2019-10-10 CN CN201980075582.0A patent/CN113330119A/zh active Pending
- 2019-10-10 JP JP2021518738A patent/JP7147060B2/ja active Active
- 2019-10-10 EP EP19871372.9A patent/EP3865578A4/en active Pending
- 2019-10-10 KR KR1020217010523A patent/KR102594583B1/ko active IP Right Grant
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010214A1 (en) | 1991-11-15 | 1993-05-27 | George Georgiou | Expression of proteins on bacterial surface |
US5356797A (en) | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
WO1993024636A1 (en) | 1992-05-29 | 1993-12-09 | The University Of British Columbia | Use of protein oprf for bacterial cell surface expression of oligopeptides |
WO1994010330A1 (en) | 1992-11-03 | 1994-05-11 | Rea, Teresa, Stanek | Fibronectin binding protein as well as its preparation |
EP0603672A2 (de) | 1992-12-23 | 1994-06-29 | BEHRINGWERKE Aktiengesellschaft | Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung |
WO1995004069A1 (en) | 1993-07-30 | 1995-02-09 | Affymax Technologies N.V. | Biotinylation of proteins |
WO2003014360A1 (en) | 2001-08-10 | 2003-02-20 | Bioleaders Corporation | SURFACE EXPRESSION VECTORS HAVING pgsBCA, THE GENE CODING POLY-GAMMA-GLUTAMATE SYNTHETASE, AND A METHOD FOR EXPRESSION OF TARGET PROTEIN AT THE SURFACE OF MICROORGANISM USING THE VECTOR |
KR100469800B1 (ko) | 2001-08-10 | 2005-02-02 | 주식회사 바이오리더스 | 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를이용한 표면 발현용 벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 |
KR20080086161A (ko) * | 2007-03-22 | 2008-09-25 | 주식회사 바이오리더스 | 신규 항시적 고발현 프로모터 및 그 용도 |
WO2010001363A1 (en) * | 2008-07-04 | 2010-01-07 | Terranol A/S | Microorganism expressing aldose-1-epimerase |
KR101471043B1 (ko) | 2009-01-08 | 2014-12-09 | 주식회사 바이오리더스 | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 |
KR20150092921A (ko) * | 2014-02-06 | 2015-08-17 | 단국대학교 천안캠퍼스 산학협력단 | 담즙산에 의해 발현이 유도되는 프로모터를 포함하는 셔틀벡터 및 이를 포함하는 조성물 |
Non-Patent Citations (28)
Title |
---|
AGTERBERG ET AL., VACCINE, vol. 8, 1990, pages 85 - 91 |
ASHIUCHI ET AL., BIOCHEM. BIOPHY. RES. COMMUNICATIONS, vol. 263, 1999, pages 6 - 12 |
BARRETT, J. T., TEXTBOOK OF IMMUNOLOGY, 1983 |
BIOTECH. BIOENG., vol. 57, no. 4, 1998, pages 430 - 437 |
CHARBIT ET AL., J. IMMUNOL., vol. 139, 1987, pages 1658 - 1664 |
DATABASE NCBI 27 February 2015 (2015-02-27), Database accession no. FM177140.1 * |
FELICI ET AL., J. MOL. BIOL., vol. 222, 1991, pages 301 - 310 |
FRANCISCO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 489, 1992, pages 2713 - 2717 |
FUCHS ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1369 - 1372 |
GEORGIOU ET AL., TIBTECH, vol. 11, 1993, pages 6 |
HEDEGAARD ET AL., GENE, vol. 85, 1989, pages 115 - 124 |
J. BACTERIOLOGY, vol. 171, 1989, pages 722 - 730 |
J. M. VAN DER VOSSEN ET AL., APPL. ENVIRON. MICROBIAL., vol. 53, 1987, pages 2452 - 2457 |
JOS F. M. K. SEEGERS, TRENDS BIOTECHNOL., vol. 20, 2002, pages 508 - 515 |
JUNG ET AL., ENZYME MICROB. TECHNOL, vol. 22, no. 5, 1998, pages 348 - 354 |
JUNG ET AL., NAT, BIOTECHNOL, vol. 16, 1998, pages 576 - 560 |
KARINA ARAUJO AIRES ET AL., APPL. ENVIRON. MICROBIOL., vol. 72, 2006, pages 745 - 752 |
KLAUSER ET AL., EMBO J, vol. 9, 1990, pages 1991 - 1999 |
KORNACKER ET AL., MOL. MICROL., vol. 4, 1990, pages 1101 - 1109 |
LEE ET AL., NAT. BIOTECHNOL, vol. 18, 2000, pages 645 - 648 |
LEE ET AL., TIBTECH, vol. 21, 2003, pages 45 - 52 |
LEE S. Y. ET AL., TRENDS BIOTECHNOL., vol. 21, 2003, pages 4552 |
LOTHAR STEIDLER ET AL., NAT. BIOTECHNOL., vol. 21, 2003, pages 785 - 789 |
NATTO, BIOCHEM. BIOPHY. RESEARCH COMM., vol. 263, 1999, pages 6 - 12 |
NEWTON ET AL., SCIENCE, vol. 244, 1989, pages 70 - 72 |
PASCALLE G. G. A. ET AL., APPL. ENVIRON. MICROBIAL., vol. 62, 1996, pages 3662 - 3667 |
PHILIPPE SLOS ET AL., APPL. ENVIRON. MICROBIAL., vol. 57, 1991, pages 1333 - 1339 |
SAMUELSON ET AL., J. BACTERIOL., vol. 177, 1995, pages 1470 - 1476 |
Also Published As
Publication number | Publication date |
---|---|
US20220033812A1 (en) | 2022-02-03 |
EP3865578A1 (en) | 2021-08-18 |
KR102594583B1 (ko) | 2023-10-27 |
CN113330119A (zh) | 2021-08-31 |
JP2022504335A (ja) | 2022-01-13 |
EP3865578A4 (en) | 2022-08-24 |
KR20210046810A (ko) | 2021-04-28 |
JP7147060B2 (ja) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020076079A2 (ko) | 락토바실러스 카제이 유래의 두 종류 프로모터를 이용한 두 가지 목적단백질의 동시 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 | |
WO2018040537A1 (zh) | 人pd-1基因敲除的cldn18.2 特异性嵌合抗原受体t细胞的制备方法以及应用 | |
WO2010079991A2 (ko) | 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균 | |
WO2017217768A1 (ko) | 온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도 | |
CN101328210A (zh) | Hiv肽,抗原,疫苗组合物,检测hiv所诱导的抗体的免疫测定试剂盒及方法 | |
WO2018074884A1 (ko) | 재조합 단백질 및 그의 용도 | |
WO2019209079A1 (en) | Nucleic acid molecules inserted expression regulation sequences, expression vector comprising nucleic acid moleclues and pharmaceutical use thereof | |
WO2019031939A2 (ko) | 암 치료를 위한 t 세포의 활성화 방법 | |
WO2011043584A2 (ko) | 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법 | |
WO2020076078A1 (ko) | 락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용 | |
WO2020004877A1 (ko) | 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를 이용한 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법 | |
WO2015199387A2 (ko) | 가용성 단백질 발현량 및 활성이 증대된 헬리코박터 파일로리 유래 α-1,3 푸코실 전달효소의 유전자와 단백질 및 α-1,3 푸코실올리고당 생산에의 응용 | |
WO2022065913A1 (ko) | 요산산화효소-알부민 접합체, 그 제조방법 및 용도 | |
WO2015199386A1 (ko) | 가용성 단백질 발현량이 증대된 헬리코박터 파일로리 유래 α-1,2 푸코실 전달효소의 유전자와 단백질 및 α-1,2 푸코실올리고당 생산에의 응용 | |
WO2012176981A1 (en) | Enhanced heterologous protein production in kluyveromyces marxianus | |
WO2018182361A1 (ko) | CRISPR/Cas 시스템과 재조합 효소 및 단일가닥 올리고디옥시리보핵산을 이용한 코리네박테리움 변이균주 제조방법 | |
WO2020235974A9 (ko) | 단일염기 치환 단백질 및 이를 포함하는 조성물 | |
WO2019022463A2 (ko) | 면역원성시스템 및 이를 포함한 동물 백신 | |
WO2010079982A2 (ko) | repE 변이유전자를 함유하는 항시적 고발현 벡터 | |
EP3334755A1 (en) | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof | |
WO2020218657A1 (ko) | 표적 특이적 crispr 변이체 | |
WO2023140697A1 (ko) | Cas 단백질 또는 이의 변이체의 스크리닝 방법, 및 이를 이용하여 제조된 Cas 단백질 또는 이의 변이체 | |
WO2023101381A1 (ko) | 구제역 바이러스 유사 입자를 생산하기 위한 백신 플랫폼 | |
WO2024049280A1 (ko) | 수퍼옥시드 디스뮤타제를 발현하는 바실러스 종 균주, 바실러스 종 균주 포자 및/또는 수퍼옥시드 디스뮤타제 및 이의 섬유화 질환 예방 또는 치료용 용도 | |
WO2023244001A1 (ko) | 면역활성 부위 융합 단백질을 포함하는 결핵 백신 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19871372 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021518738 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20217010523 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019871372 Country of ref document: EP Effective date: 20210510 |